Presented at: AACR Annual Meeting 2022
On: Apr 11, 2022
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase
By: L. Roeker, A. Mato1, J. Brown, C. Coombs, N. Shah, et. al.